Pharmicell Reports Strong 2025 Earnings, Increases Dividend to 50 KRW per Share and Cancels Treasury Shares, While Continuing to Improve Governance
2025 consolidated revenue reached 114.06B KRW, operating profit 34.30B KRW, net income 40.29B KRW, surging 76%, 637%, and 536% YoY respectively, driven by strong sales of low-dielectric electronic materials. This represents a significant improvement in fundamentals and strengthens shareholder value.
A year-end cash dividend of 50 KRW per common share (total 3.00B KRW) was declared for fiscal 2025, a 150% increase from 20 KRW in the prior year. The cash dividend payout ratio is 7.4%, still low but consistent with a two-year track record of dividend payments, signaling commitment to shareholder returns.
On March 26, 2026, the company completed the cancellation of 12,950 treasury shares (approx. 0.02% of total outstanding shares). Although the amount is negligible, it demonstrates a willingness to return capital to shareholders.
The largest shareholder group (6 persons) holds only 9.36%, while minority shareholders hold 83.49%, giving them significant influence. The board comprises 3 inside directors, 3 independent directors, and 1 non-executive director (total 7). The audit committee consists entirely of independent directors, and an accounting expert was appointed in 2026, strengthening expertise.
Several key governance indicators remain non-compliant, including dividend policy disclosure, CEO succession planning, and internal control policies. However, the company stated it is reviewing the establishment of a shareholder return policy and internal regulations, indicating a commitment to improvement.
No convertible bonds, bonds with warrants, or other equity-linked instruments are outstanding, eliminating dilution risk for existing shareholders. No additional capital-raising plans are currently in place.
In October 2025, the company purchased a property worth 250M KRW from the largest shareholder (CEO Kim Hyun-soo) for employee welfare purposes. The transaction was approved by the board with the interested party's voting rights restricted, ensuring proper internal control procedures.
[AI Summary]The strong 2025 earnings growth and expanded dividends/treasury share cancellation are positive for shareholder value, but the lack of dividend predictability and some governance shortcomings pose investment risks. However, the absence of dilution risk and planned governance improvements make this a net positive over the medium to long term.